person · Reporting owner

Rubin Steven D

Disclosed activity across 9 companies

Tapewire entity: 25378
SEC CIK: 0001381874

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cocrystal Pharma, Inc.COCP · Entity 7621	Director	January 09, 2026	January 13, 2026
Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180	Director	June 08, 2026	June 11, 2026
Entera Bio Ltd.[ENTX] · Entity 5464	Director	August 07, 2026	August 07, 2026
Fluent, Inc.COGT · Entity 6736	Director	April 13, 2017	April 17, 2017
Niagen Bioscience, Inc.NAGE · Entity 6146	Director	June 24, 2026	June 26, 2026
OPKO HEALTH, INC.OPK · Entity 4891	Director · Executive VP-Administration	July 24, 2026	July 28, 2026
Red Violet, Inc.RDVT · Entity 4826	Director	June 04, 2026	June 05, 2026
VBI Vaccines Inc/BCVBIV · Entity 111039	Director	June 14, 2018	June 18, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cocrystal Pharma, Inc.

Report date January 09, 2026 · Filed January 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2036-01-09	Direct	16,410	Reported balance After 2026-01-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-09 · Grant · Acquired 16,410 · Balance 16,410 F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

Eloxx Pharmaceuticals, Inc.

Report date June 08, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2036-06-08	Direct	4,018	Reported balance After 2026-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-08 · Grant · Acquired 4,018 · Balance 4,018 F1: The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Entera Bio Ltd.

Report date August 07, 2026 · Filed August 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, par value NIS 0.0000769 per shareSEC Table I · non-derivative	Direct	34,117	Reported balance After 2026-08-07 transaction · row 1 1 source row Row 1 · 2026-08-07 · Grant · Acquired 19,117 · Balance 34,117 F1: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2036-05-07	Direct	33,368	Reported balance After 2026-08-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-07 · Grant · Acquired 33,368 · Balance 33,368 F2: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 1, 2026, with one third of the options vesting on February 1, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2036-05-07	Direct	43,405	Reported balance After 2026-08-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-07 · Grant · Acquired 43,405 · Balance 43,405 F3: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).

Filing footnotes · ownership attribution and instrument terms

F1: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

F2: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 1, 2026, with one third of the options vesting on February 1, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).

F3: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).

Fluent, Inc.

Report date April 13, 2017 · Filed April 17, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,000	Reported balance After 2017-04-13 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2017-04-13 · Grant · Acquired 20,000 · Balance 20,000 F1: On April 13, 2017, the reporting person received a grant of 20,000 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis. The RSUs vest in three approximately equal installments on June 1, 2017, 2018 and 2019, subject to accelerated vesting under certain conditions. F2: Within 30 days of the effective grant date, the reporting person may elect to defer delivery of any vested RSUs until a later date.
Common StockSEC Table I · non-derivative	Direct	5,000	Reported balance After 2017-04-13 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2017-04-13 · Grant · Acquired 5,000 · Balance 5,000 F2: Within 30 days of the effective grant date, the reporting person may elect to defer delivery of any vested RSUs until a later date. F3: On April 13, 2017, the reporting person received a grant of 5,000 RSUs, convertible into common stock of the issuer on a one-for-one basis. The restricted stock units vest on June 1, 2017, subject to accelerated vesting under certain conditions.
Common StockSEC Table I · non-derivative	Direct	100,000	Reported balance Holding disclosure · report date 2017-04-13 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 100,000 F4: On November 16, 2015, the reporting person received a grant, subject to stockholder approval which was obtained June 1, 2016, of 100,000 RSUs, convertible into common stock of the issuer on a one-for-one basis. The RSUs vest in three equal annual installments beginning November 16, 2016 (the "Time Conditions") provided, however, that no tranche of RSUs will vest until it is determined that Cogint, Inc. has exceeded certain revenue targets and achieved positive EBITDA in any one fiscal year during the vesting period (the "Performance Conditions"). Cogint, Inc. determined the Performance Conditions were met effective March 14, 2017. As such, the subsequent tranches vest equally on November 16, 2017 and November 16, 2018. F5: The RSUs will immediately vest upon (i) a Change of Control, or (ii) the reporting person's death or disability. F6: The reporting person has elected to defer delivery of any vested RSUs until the reporting person's separation of service from the Company or death or disability.
Common StockSEC Table I · non-derivative	Direct	213,255	Reported balance Holding disclosure · report date 2017-04-13 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 213,255
Common StockSEC Table I · non-derivative	Direct	25,000	Reported balance Holding disclosure · report date 2017-04-13 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 25,000 F7: Represents RSUs, convertible into common stock of the issuer on a one-for-one basis. The RSUs vest on March 21, 2018, subject to accelerated vesting under certain conditions.

Filing footnotes · ownership attribution and instrument terms

F1: On April 13, 2017, the reporting person received a grant of 20,000 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis. The RSUs vest in three approximately equal installments on June 1, 2017, 2018 and 2019, subject to accelerated vesting under certain conditions.

F2: Within 30 days of the effective grant date, the reporting person may elect to defer delivery of any vested RSUs until a later date.

F3: On April 13, 2017, the reporting person received a grant of 5,000 RSUs, convertible into common stock of the issuer on a one-for-one basis. The restricted stock units vest on June 1, 2017, subject to accelerated vesting under certain conditions.

F4: On November 16, 2015, the reporting person received a grant, subject to stockholder approval which was obtained June 1, 2016, of 100,000 RSUs, convertible into common stock of the issuer on a one-for-one basis. The RSUs vest in three equal annual installments beginning November 16, 2016 (the "Time Conditions") provided, however, that no tranche of RSUs will vest until it is determined that Cogint, Inc. has exceeded certain revenue targets and achieved positive EBITDA in any one fiscal year during the vesting period (the "Performance Conditions"). Cogint, Inc. determined the Performance Conditions were met effective March 14, 2017. As such, the subsequent tranches vest equally on November 16, 2017 and November 16, 2018.

F5: The RSUs will immediately vest upon (i) a Change of Control, or (ii) the reporting person's death or disability.

F6: The reporting person has elected to defer delivery of any vested RSUs until the reporting person's separation of service from the Company or death or disability.

F7: Represents RSUs, convertible into common stock of the issuer on a one-for-one basis. The RSUs vest on March 21, 2018, subject to accelerated vesting under certain conditions.

Niagen Bioscience, Inc.

Report date June 24, 2026 · Filed June 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2036-06-23	Direct	31,746	Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-24 · Grant · Acquired 31,746 · Balance 31,746 F1: Option vests 100% on June 24, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Option vests 100% on June 24, 2027.

OPKO HEALTH, INC.

Report date July 24, 2026 · Filed July 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,571,966	Reported balance After 2026-07-24 transaction · row 1 1 source row Row 1 · 2026-07-24 · Tax withholding · Disposed 53,266 · Balance 6,571,966 F1: This number represents shares of common stock par value $0.01 per shares of OPKO Health, Inc. withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: This number represents shares of common stock par value $0.01 per shares of OPKO Health, Inc. withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units.

Red Violet, Inc.

Report date June 04, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	147,767	Reported balance After 2026-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 2,179 · Balance 147,767 F1: On June 4, 2026, the reporting person received a grant of 2,179 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vests on the earlier of one year from the date of grant or the 2027 annual meeting of stockholders, subject to accelerated vesting under certain conditions. F2: Includes 3,600 RSUs originally granted on November 30, 2023, convertible into common stock of the issuer on a one-for-one basis, which vests on December 1, 2026, subject to accelerated vesting under certain conditions. F3: Includes 5,333 RSUs originally granted on November 4, 2024, convertible into common stock of the issuer on a one-for-one basis, which vests in two equal installments on each of November 1, 2026 and November 1, 2027, subject to accelerated vesting under certain circumstances. F4: Includes 59,200 vested RSUs in which the reporting person has elected to defer delivery until the reporting person's separation of service from the issuer or death or disability. F5: Includes 4,450 RSUs originally granted on December 19, 2025, convertible into common stock of the issuer on a one-for-one basis, which vests in three equal installments on each of December 1, 2026, December 1, 2027, and December 1, 2028, subject to accelerated vesting under certain circumstances.

Filing footnotes · ownership attribution and instrument terms

F1: On June 4, 2026, the reporting person received a grant of 2,179 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vests on the earlier of one year from the date of grant or the 2027 annual meeting of stockholders, subject to accelerated vesting under certain conditions.

F2: Includes 3,600 RSUs originally granted on November 30, 2023, convertible into common stock of the issuer on a one-for-one basis, which vests on December 1, 2026, subject to accelerated vesting under certain conditions.

F3: Includes 5,333 RSUs originally granted on November 4, 2024, convertible into common stock of the issuer on a one-for-one basis, which vests in two equal installments on each of November 1, 2026 and November 1, 2027, subject to accelerated vesting under certain circumstances.

F4: Includes 59,200 vested RSUs in which the reporting person has elected to defer delivery until the reporting person's separation of service from the issuer or death or disability.

F5: Includes 4,450 RSUs originally granted on December 19, 2025, convertible into common stock of the issuer on a one-for-one basis, which vests in three equal installments on each of December 1, 2026, December 1, 2027, and December 1, 2028, subject to accelerated vesting under certain circumstances.

VBI Vaccines Inc/BC

Report date June 14, 2018 · Filed June 18, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Shares, no par value per shareSEC Table I · non-derivative	Direct	56,250	Reported balance After 2018-06-14 transaction · row 1 1 source row Row 1 · 2018-06-14 · Exercise / conversion · Acquired 18,750 · Balance 56,250 F1: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date.
Restricted Stock Units (RSUs)SEC Table II · derivative / convertible security	Direct	18,750	Reported balance After 2018-06-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-14 · Exercise / conversion · Disposed 18,750 · Balance 18,750 F1: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F2: The restricted stock units vest 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date.

F2: The restricted stock units vest 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Castle Brands Inc

Report date October 08, 2019 · Filed October 09, 2019

Section 16 reporting ended · disclosed 2019-10-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2019-10-08 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-10-08 · Other · Disposed 108,500 · Balance 22,500 F1: On October 8, 2019, Rook Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Austin, Nichols & Co., Inc. ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Castle Brands Inc. ("Issuer") pursuant to that certain Agreement and Plan of Merger, dated August 28, 2019 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on October 9, 2019, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on October 9, 2019. F2: Represents shares tendered to the Purchaser in connection with the Tender Offer. Row 2 · 2019-10-08 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: On October 8, 2019, Rook Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Austin, Nichols & Co., Inc. ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Castle Brands Inc. ("Issuer") pursuant to that certain Agreement and Plan of Merger, dated August 28, 2019 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on October 9, 2019, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on October 9, 2019. F3: In accordance with the terms of the Merger Agreement, the restricted stock awards held by the reporting person were deemed to be fully vested and converted at the effective time of the Merger into the right to receive a cash payment, without interest, equal to the product of (i) the aggregate number of shares of the Issuer's Common Stock in respect of such restricted stock awards multiplied by (ii) $1.27, less any taxes required to be withheld.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2020-02-04	Direct	Reported balance After 2019-10-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-10-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On October 8, 2019, Rook Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Austin, Nichols & Co., Inc. ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Castle Brands Inc. ("Issuer") pursuant to that certain Agreement and Plan of Merger, dated August 28, 2019 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on October 9, 2019, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on October 9, 2019. F4: In accordance with the terms of the Merger Agreement, this stock option held by the reporting person was deemed to be fully vested and cancelled and converted at the effective time of the Merger into the right to receive a cash payment, without interest, equal to the product of (i) the aggregate number of shares of the Issuer's Common Stock subject to such stock option multiplied by (ii) the excess of $1.27 over the per share exercise price of such stock option, less any taxes required to be withheld.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.27 · Expires 2021-09-12	Direct	Reported balance After 2019-10-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-10-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On October 8, 2019, Rook Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Austin, Nichols & Co., Inc. ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Castle Brands Inc. ("Issuer") pursuant to that certain Agreement and Plan of Merger, dated August 28, 2019 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on October 9, 2019, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on October 9, 2019. F4: In accordance with the terms of the Merger Agreement, this stock option held by the reporting person was deemed to be fully vested and cancelled and converted at the effective time of the Merger into the right to receive a cash payment, without interest, equal to the product of (i) the aggregate number of shares of the Issuer's Common Stock subject to such stock option multiplied by (ii) the excess of $1.27 over the per share exercise price of such stock option, less any taxes required to be withheld.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2022-10-15	Direct	Reported balance After 2019-10-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-10-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On October 8, 2019, Rook Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Austin, Nichols & Co., Inc. ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Castle Brands Inc. ("Issuer") pursuant to that certain Agreement and Plan of Merger, dated August 28, 2019 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on October 9, 2019, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on October 9, 2019. F4: In accordance with the terms of the Merger Agreement, this stock option held by the reporting person was deemed to be fully vested and cancelled and converted at the effective time of the Merger into the right to receive a cash payment, without interest, equal to the product of (i) the aggregate number of shares of the Issuer's Common Stock subject to such stock option multiplied by (ii) the excess of $1.27 over the per share exercise price of such stock option, less any taxes required to be withheld.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2024-03-05	Direct	Reported balance After 2019-10-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-10-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On October 8, 2019, Rook Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Austin, Nichols & Co., Inc. ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Castle Brands Inc. ("Issuer") pursuant to that certain Agreement and Plan of Merger, dated August 28, 2019 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on October 9, 2019, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on October 9, 2019. F4: In accordance with the terms of the Merger Agreement, this stock option held by the reporting person was deemed to be fully vested and cancelled and converted at the effective time of the Merger into the right to receive a cash payment, without interest, equal to the product of (i) the aggregate number of shares of the Issuer's Common Stock subject to such stock option multiplied by (ii) the excess of $1.27 over the per share exercise price of such stock option, less any taxes required to be withheld.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.46 · Expires 2025-03-26	Direct	Reported balance After 2019-10-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-10-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On October 8, 2019, Rook Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Austin, Nichols & Co., Inc. ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Castle Brands Inc. ("Issuer") pursuant to that certain Agreement and Plan of Merger, dated August 28, 2019 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on October 9, 2019, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on October 9, 2019. F5: In accordance with the terms of the Merger Agreement, this stock option was cancelled at the effective time of the Merger because the exercise price of the stock option exceeded $1.27 per share.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2026-03-17	Direct	Reported balance After 2019-10-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-10-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On October 8, 2019, Rook Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Austin, Nichols & Co., Inc. ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Castle Brands Inc. ("Issuer") pursuant to that certain Agreement and Plan of Merger, dated August 28, 2019 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on October 9, 2019, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on October 9, 2019. F4: In accordance with the terms of the Merger Agreement, this stock option held by the reporting person was deemed to be fully vested and cancelled and converted at the effective time of the Merger into the right to receive a cash payment, without interest, equal to the product of (i) the aggregate number of shares of the Issuer's Common Stock subject to such stock option multiplied by (ii) the excess of $1.27 over the per share exercise price of such stock option, less any taxes required to be withheld.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2027-02-28	Direct	Reported balance After 2019-10-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-10-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On October 8, 2019, Rook Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Austin, Nichols & Co., Inc. ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Castle Brands Inc. ("Issuer") pursuant to that certain Agreement and Plan of Merger, dated August 28, 2019 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on October 9, 2019, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on October 9, 2019. F4: In accordance with the terms of the Merger Agreement, this stock option held by the reporting person was deemed to be fully vested and cancelled and converted at the effective time of the Merger into the right to receive a cash payment, without interest, equal to the product of (i) the aggregate number of shares of the Issuer's Common Stock subject to such stock option multiplied by (ii) the excess of $1.27 over the per share exercise price of such stock option, less any taxes required to be withheld.

Filing footnotes · ownership attribution and instrument terms

F1: On October 8, 2019, Rook Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Austin, Nichols & Co., Inc. ("Parent"), successfully completed the tender offer ("Tender Offer") for all issued and outstanding shares of the common stock of Castle Brands Inc. ("Issuer") pursuant to that certain Agreement and Plan of Merger, dated August 28, 2019 (the "Merger Agreement"), by and among Issuer, Parent and Purchaser. Following the Tender Offer, on October 9, 2019, Purchaser merged with and into Issuer with Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). In connection with the Merger, the reporting person is no longer a director of Issuer, effective on October 9, 2019.

F2: Represents shares tendered to the Purchaser in connection with the Tender Offer.

F3: In accordance with the terms of the Merger Agreement, the restricted stock awards held by the reporting person were deemed to be fully vested and converted at the effective time of the Merger into the right to receive a cash payment, without interest, equal to the product of (i) the aggregate number of shares of the Issuer's Common Stock in respect of such restricted stock awards multiplied by (ii) $1.27, less any taxes required to be withheld.

F4: In accordance with the terms of the Merger Agreement, this stock option held by the reporting person was deemed to be fully vested and cancelled and converted at the effective time of the Merger into the right to receive a cash payment, without interest, equal to the product of (i) the aggregate number of shares of the Issuer's Common Stock subject to such stock option multiplied by (ii) the excess of $1.27 over the per share exercise price of such stock option, less any taxes required to be withheld.

F5: In accordance with the terms of the Merger Agreement, this stock option was cancelled at the effective time of the Merger because the exercise price of the stock option exceeded $1.27 per share.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 07, 2026 Filed Aug 7, 2026 20:23 UTC	Entera Bio Ltd. [ENTX] · Entity 5464	GrantStock Option (right to buy) · Derivative	43,405	$0.00 Strike: $1.37	$0.00	Disclosure SEC source: 0001178913-26-003957 · zk2635885.xml · derivative · entry 3 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,405 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 43,405 shares Expires 2036-05-07 F3 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan). Read SEC document
August 07, 2026 Filed Aug 7, 2026 20:23 UTC	Entera Bio Ltd. [ENTX] · Entity 5464	GrantStock Option (right to buy) · Derivative	33,368	$0.00 Strike: $1.37	$0.00	Disclosure SEC source: 0001178913-26-003957 · zk2635885.xml · derivative · entry 2 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,368 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 33,368 shares Expires 2036-05-07 F2 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 1, 2026, with one third of the options vesting on February 1, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")). Read SEC document
August 07, 2026 Filed Aug 7, 2026 20:23 UTC	Entera Bio Ltd. [ENTX] · Entity 5464	GrantOrdinary Shares, par value NIS 0.0000769 per share	19,117	$0.00	$0.00	Disclosure SEC source: 0001178913-26-003957 · zk2635885.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,117 F1 · kind: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026. Read SEC document
July 24, 2026 Filed Jul 28, 2026 20:21 UTC	OPKO HEALTH, INC. OPK · Entity 4891	Tax withholdingCommon Stock	53,266	$1.22	$64,984.52	Disclosure SEC source: 0001193125-26-321041 · ownership.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director · Executive VP-Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,571,966 F1 · shares: This number represents shares of common stock par value $0.01 per shares of OPKO Health, Inc. withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. Read SEC document
June 24, 2026 Filed Jun 26, 2026 21:55 UTC	Niagen Bioscience, Inc. NAGE · Entity 6146	GrantStock Option (right to buy) · Derivative	31,746	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001381874-26-000001 · wk-form4_1782510955.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,746 Underlying: Common Stock · 31,746 shares Expires 2036-06-23 F1 · derivative.exercise_date: Option vests 100% on June 24, 2027. Read SEC document
June 08, 2026 Filed Jun 11, 2026 00:00 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	GrantStock Option (Right to Buy) · Derivative	4,018	$0.00 Strike: $11.00	$0.00	Disclosure SEC source: 0001193125-26-266275 · ownership.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,018 Underlying: Common Stock · 4,018 shares Expires 2036-06-08 F1 · derivative.exercise_date: The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document
June 04, 2026 Filed Jun 5, 2026 20:57 UTC	Red Violet, Inc. RDVT · Entity 4826	GrantCommon Stock	2,179	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-259844 · ownership.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,767 F1 · shares: On June 4, 2026, the reporting person received a grant of 2,179 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vests on the earlier of one year from the date of grant or the 2027 annual meeting of stockholders, subject to accelerated vesting under certain conditions. F1 · price: On June 4, 2026, the reporting person received a grant of 2,179 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vests on the earlier of one year from the date of grant or the 2027 annual meeting of stockholders, subject to accelerated vesting under certain conditions. F1 · balance_after: On June 4, 2026, the reporting person received a grant of 2,179 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vests on the earlier of one year from the date of grant or the 2027 annual meeting of stockholders, subject to accelerated vesting under certain conditions. F2 · balance_after: Includes 3,600 RSUs originally granted on November 30, 2023, convertible into common stock of the issuer on a one-for-one basis, which vests on December 1, 2026, subject to accelerated vesting under certain conditions. F3 · balance_after: Includes 5,333 RSUs originally granted on November 4, 2024, convertible into common stock of the issuer on a one-for-one basis, which vests in two equal installments on each of November 1, 2026 and November 1, 2027, subject to accelerated vesting under certain circumstances. F4 · balance_after: Includes 59,200 vested RSUs in which the reporting person has elected to defer delivery until the reporting person's separation of service from the issuer or death or disability. F5 · balance_after: Includes 4,450 RSUs originally granted on December 19, 2025, convertible into common stock of the issuer on a one-for-one basis, which vests in three equal installments on each of December 1, 2026, December 1, 2027, and December 1, 2028, subject to accelerated vesting under certain circumstances. Read SEC document
February 12, 2026 Filed Feb 17, 2026 13:30 UTC	Entera Bio Ltd. [ENTX] · Entity 5464	PurchaseOrdinary Shares, par value NIS 0.0000769 per share	5,000	$1.49	$7,450.00	Disclosure SEC source: 0001178913-26-000508 · zk2634371.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Read SEC document
February 09, 2026 Filed Feb 11, 2026 13:44 UTC	Entera Bio Ltd. [ENTX] · Entity 5464	PurchaseOrdinary Shares, par value NIS 0.0000769 per share	10,000	$1.20	$12,000.00	Disclosure SEC source: 0001178913-26-000412 · zk2634333.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Read SEC document
January 24, 2026 Filed May 8, 2026 21:12 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	Exercise / conversionRestricted Stock Units · Derivative	1,875	$0.00	$0.00	Disclosure SEC source: 0001193125-26-214983 · ownership.xml · derivative · entry 3 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter. F3 · derivative.expiration_date: The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter. Read SEC document
January 24, 2026 Filed May 8, 2026 21:12 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	Exercise / conversionCommon Stock	1,875	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-214983 · ownership.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:10 UTC	Cocrystal Pharma, Inc. COCP · Entity 7621	GrantStock Options (Right to Buy) · Derivative	16,410	$0.00 Strike: $1.10	$0.00	Disclosure SEC source: 0001493152-26-002033 · ownership.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,410 Underlying: Common Stock · 16,410 shares Expires 2036-01-09 F1 · security: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date. F1 · derivative.exercise_date: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date. Read SEC document
December 19, 2025 Filed Dec 22, 2025 23:52 UTC	Red Violet, Inc. RDVT · Entity 4826	GrantCommon Stock	4,450	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-25-329097 · ownership.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,588 F1 · shares: On December 19, 2025, the reporting person received a grant of 4,450 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of December 1, 2026, December 1, 2027, and December 1, 2028, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 2,130 RSUs for serving as a member of the Company's Board of Directors, 1,625 RSUs for serving as a member of the Audit Committee and 695 RSUs for serving as the Chair of the Compensation Committee. F1 · price: On December 19, 2025, the reporting person received a grant of 4,450 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of December 1, 2026, December 1, 2027, and December 1, 2028, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 2,130 RSUs for serving as a member of the Company's Board of Directors, 1,625 RSUs for serving as a member of the Audit Committee and 695 RSUs for serving as the Chair of the Compensation Committee. F1 · balance_after: On December 19, 2025, the reporting person received a grant of 4,450 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of December 1, 2026, December 1, 2027, and December 1, 2028, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 2,130 RSUs for serving as a member of the Company's Board of Directors, 1,625 RSUs for serving as a member of the Audit Committee and 695 RSUs for serving as the Chair of the Compensation Committee. F2 · balance_after: Includes 3,600 RSUs originally granted on November 30, 2023, convertible into common stock of the issuer on a one-for-one basis, which vests on December 1, 2026. F3 · balance_after: Includes 5,333 RSUs originally granted on November 4, 2024, convertible into common stock of the issuer on a one-for-one basis, which vests in two equal installments on each of November 1, 2026 and November 1, 2027, subject to accelerated vesting under certain circumstances. F4 · balance_after: Includes 59,200 vested RSUs in which the reporting person has elected to defer delivery until the reporting person's separation of service from the issuer or death or disability. Read SEC document
September 19, 2025 Filed May 8, 2026 21:12 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	GrantStock Option (Right to Buy) · Derivative	179,854	$0.00 Strike: $0.15	$0.00	Disclosure SEC source: 0001193125-26-214983 · ownership.xml · derivative · entry 2 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,854 Underlying: Common Stock · 179,854 shares Expires 2035-09-19 F2 · derivative.exercise_date: The stock option vested as to 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document
June 24, 2025 Filed Jun 26, 2025 00:29 UTC	Niagen Bioscience, Inc. NAGE · Entity 6146	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $14.13	$0.00	Disclosure SEC source: 0001628280-25-033063 · wk-form4_1750897763.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: Option vests 100% on June 24, 2026. Read SEC document
May 27, 2025 Filed May 29, 2025 21:04 UTC	OPKO HEALTH, INC. OPK · Entity 4891	GrantStock Option (Right to Buy) · Derivative	437,500	$0.00 Strike: $1.31	$0.00	Disclosure SEC source: 0000950170-25-079112 · ownership.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director · Executive VP-Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,500 Underlying: Common Stock · 437,500 shares Expires 2035-05-26 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 27, 2026. Read SEC document
March 19, 2025 Filed Mar 21, 2025 22:30 UTC	Red Violet, Inc. RDVT · Entity 4826	SaleCommon Stock	10,000	$38.93	$389,300.00	Disclosure SEC source: 0000950170-25-043394 · ownership.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,138 F1 · price: The shares were sold in multiple transactions at prices ranging from $38.89 to $38.96, inclusive, with a weighted average price per share of $38.93. The reporting person undertakes to provide Red Violet, Inc., any security holder of Red Violet, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the ranges set forth in this footnote. F2 · balance_after: Includes 8,000 Restricted Stock Units ("RSUs"), originally granted on November 4, 2024, convertible into common stock of the issuer on a one-for-one basis, which vests in approximately three equal installments on each of November 1, 2025, November 1, 2026, and November 1, 2027, subject to accelerated vesting under certain conditions. F3 · balance_after: Includes 7,200 RSUs originally granted on November 30, 2023, convertible into common stock of the issuer on a one-for-one basis, which vests in approximately two equal installments on each of December 1, 2025, and December 1, 2026, subject to accelerated vesting under certain conditions. F4 · balance_after: Includes 3,600 RSUs originally granted on October 12, 2022, convertible into common stock of the issuer on a one-for-one basis, which vests on November 1, 2025, subject to accelerated vesting under certain conditions. F5 · balance_after: Includes 55,600 vested RSUs in which the reporting person has elected to defer delivery until the reporting person's separation of service from the issuer or death or disability. Read SEC document
January 24, 2025 Filed Jan 28, 2025 22:36 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	Exercise / conversionRestricted Stock Units · Derivative	3,750	$0.00	$0.00	Disclosure SEC source: 0001104659-25-006783 · tm254730-3_4seq1.xml · derivative · entry 2 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_price: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. F2 · price: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. F2 · derivative.exercise_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. F2 · derivative.expiration_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. Read SEC document
January 24, 2025 Filed Jan 28, 2025 22:36 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	Exercise / conversionCommon Stock	3,750	$0.00	$0.00	Disclosure SEC source: 0001104659-25-006783 · tm254730-3_4seq1.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 04, 2024 Filed Nov 5, 2024 23:53 UTC	Red Violet, Inc. RDVT · Entity 4826	GrantCommon Stock	8,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-121713 · ownership.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,138 F1 · shares: On November 4, 2024, the reporting person received a grant of 8,000 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of November 1, 2025, November 1, 2026, and November 1, 2027, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 3,760 RSUs for serving as a member of the Company's Board of Directors, 2,960 RSUs for serving as a member of the Audit Committee and 1,280 RSUs for serving as the Chair of the Compensatio Committee. F1 · price: On November 4, 2024, the reporting person received a grant of 8,000 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of November 1, 2025, November 1, 2026, and November 1, 2027, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 3,760 RSUs for serving as a member of the Company's Board of Directors, 2,960 RSUs for serving as a member of the Audit Committee and 1,280 RSUs for serving as the Chair of the Compensatio Committee. F1 · balance_after: On November 4, 2024, the reporting person received a grant of 8,000 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of November 1, 2025, November 1, 2026, and November 1, 2027, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 3,760 RSUs for serving as a member of the Company's Board of Directors, 2,960 RSUs for serving as a member of the Audit Committee and 1,280 RSUs for serving as the Chair of the Compensatio Committee. F2 · balance_after: Includes 10,800 RSUs originally granted on November 30, 2023, convertible into common stock of the issuer on a one-for-one basis, which vests in approximately three equal installments on each of December 1, 2024, December 1, 2025, and December 1, 2026, subject to accelerated vesting under certain conditions. F3 · balance_after: Includes 3,600 RSUs originally granted on October 12, 2022, convertible into common stock of the issuer on a one-for-one basis, which vests on November 1, 2025, subject to accelerated vesting under certain conditions. F4 · balance_after: Includes 55,600 vested RSUs in which the reporting person has elected to defer delivery until the reporting person's separation of service from the issuer or death or disability. Read SEC document
October 16, 2024 Filed Oct 17, 2024 20:01 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	GrantCommon Stock	12,000	$0.00	$0.00	Disclosure SEC source: 0001104659-24-109523 · tm2426349-3_4seq1.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 F1 · kind: This restricted stock grant was made pursuant to the Issuer's 2018 Equity Incentive Plan and vests as to 50% of the shares on October 16, 2025 and in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document
October 09, 2024 Filed Oct 11, 2024 20:05 UTC	Cocrystal Pharma, Inc. COCP · Entity 7621	GrantCommon Stock	18,957	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-24-040905 · ownership.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,660,242 F1 · security: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan. F1 · price: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by the Board of Directors of the Issuer. One half of the RSUs are fully vested, with the balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date. Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery. The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan. Read SEC document
July 24, 2024 Filed Jul 26, 2024 23:11 UTC	OPKO HEALTH, INC. OPK · Entity 4891	GrantCommon Stock	437,500	$0.00	$0.00	Disclosure SEC source: 0000950170-24-087034 · ownership.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director · Executive VP-Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,625,232 F1 · security: Each restricted stock unit represents a contingent right to receive one share of OPKO common stock upon the vesting of the award. The restricted stock units vest 50% on the second anniversary of the grant date, then 25% on each of the following two years. Read SEC document
June 20, 2024 Filed Jun 24, 2024 21:45 UTC	Niagen Bioscience, Inc. CDXC · Entity 6146	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $2.71	$0.00	Disclosure SEC source: 0001628280-24-029653 · wk-form4_1719265494.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: Option vests 100% on June 20, 2025. Read SEC document
January 24, 2024 Filed Jan 26, 2024 21:33 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	GrantRestricted Stock Units · Derivative	7,500	$0.00	$0.00	Disclosure SEC source: 0001104659-24-007293 · tm244260-3_4seq1.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. F2 · derivative.expiration_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. Read SEC document
January 05, 2024 Filed Jan 5, 2024 18:39 UTC	OPKO HEALTH, INC. OPK · Entity 4891	PurchaseCommon Stock	10,000	$0.87	$8,669.00	Disclosure SEC source: 0000950170-24-002380 · ownership.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director · Executive VP-Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,187,732 Read SEC document
November 30, 2023 Filed Dec 4, 2023 23:30 UTC	Red Violet, Inc. RDVT · Entity 4826	GrantCommon Stock	10,800	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-057303 · doc4.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,138 F1 · shares: On November 30, 2023, the reporting person received a grant of 10,800 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of December 1, 2024, December 1, 2025 and December 1, 2026, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 5,000 RSUs for serving as a member of the Company's Board of Directors, 4,000 RSUs for serving on the Audit Committee and 1,800 RSUs for serving as the Chair of the Compensation Committee. F1 · price: On November 30, 2023, the reporting person received a grant of 10,800 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of December 1, 2024, December 1, 2025 and December 1, 2026, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 5,000 RSUs for serving as a member of the Company's Board of Directors, 4,000 RSUs for serving on the Audit Committee and 1,800 RSUs for serving as the Chair of the Compensation Committee. F1 · balance_after: On November 30, 2023, the reporting person received a grant of 10,800 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of December 1, 2024, December 1, 2025 and December 1, 2026, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 5,000 RSUs for serving as a member of the Company's Board of Directors, 4,000 RSUs for serving on the Audit Committee and 1,800 RSUs for serving as the Chair of the Compensation Committee. F2 · balance_after: Includes 2,966 RSUs convertible into common stock originally granted on September 24, 2021. The RSUs vest on October 1, 2024, subject to accelerated vesting under certain conditions. F3 · balance_after: Includes 7,200 RSUs originally granted on October 12, 2022. The RSUs vest in approximately two equal installments on each of November 1, 2024, and November 1, 2025, subject to accelerated vesting under certain conditions. F4 · balance_after: Includes 49,034 vested RSUs in which the reporting person has elected to defer delivery until the reporting person's separation of service from the issuer or death or disability. Read SEC document
November 10, 2023 Filed Nov 13, 2023 13:21 UTC	OPKO HEALTH, INC. OPK · Entity 4891	PurchaseCommon Stock	10,000	$1.30	$13,000.00	Disclosure SEC source: 0001209191-23-054917 · doc4.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director · Executive VP-Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,177,732 Read SEC document
July 18, 2023 Filed Jul 20, 2023 20:05 UTC	Cocrystal Pharma, Inc. COCP · Entity 7621	GrantStock Options (Right to Buy) · Derivative	17,233	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001493152-23-025078 · ownership.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,233 Underlying: Common Stock · 17,233 shares Expires 2033-07-18 F1 · derivative.exercise_date: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 18, 2024 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2024, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date. Read SEC document
June 15, 2023 Filed Jun 16, 2023 21:28 UTC	Niagen Bioscience, Inc. CDXC · Entity 6146	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $1.67	$0.00	Disclosure SEC source: 0001628280-23-022537 · wk-form4_1686950874.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: Option vests 100% on June 15, 2024. Read SEC document
May 25, 2023 Filed May 30, 2023 20:13 UTC	Niagen Bioscience, Inc. CDXC · Entity 6146	PurchaseCommon Stock	7,000	$1.46	$10,220.00	Disclosure SEC source: 0001628280-23-020112 · wk-form4_1685477593.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Read SEC document
May 18, 2023 Filed May 19, 2023 20:37 UTC	OPKO HEALTH, INC. OPK · Entity 4891	GrantStock Option (Right to Buy) · Derivative	700,000	$0.00 Strike: $1.58	$0.00	Disclosure SEC source: 0001209191-23-031034 · doc4.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director · Executive VP-Administration 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 18, 2024. Read SEC document
January 30, 2023 Filed Jan 31, 2023 21:09 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	GrantStock Options (Right to Buy) · Derivative	2,859	$0.00 Strike: $4.00	$0.00	Disclosure SEC source: 0001104659-23-008601 · tm234943-3_4seq1.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,859 Underlying: Common Stock · 2,859 shares Expires 2033-01-30 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document
October 12, 2022 Filed Oct 13, 2022 22:56 UTC	Red Violet, Inc. RDVT · Entity 4826	GrantCommon Stock	10,800	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-053609 · doc4.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,338 F1 · shares: On October 12, 2022, the reporting person received a grant of 10,800 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of November 1, 2023, November 1, 2024 and November 1, 2025, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 5,000 RSUs for serving as a member of the Company's Board of Directors, 4,000 RSUs for serving on the Audit Committee and 1,800 RSUs for serving as the Chair of the Compensation Committee. F1 · price: On October 12, 2022, the reporting person received a grant of 10,800 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of November 1, 2023, November 1, 2024 and November 1, 2025, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 5,000 RSUs for serving as a member of the Company's Board of Directors, 4,000 RSUs for serving on the Audit Committee and 1,800 RSUs for serving as the Chair of the Compensation Committee. F1 · balance_after: On October 12, 2022, the reporting person received a grant of 10,800 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of November 1, 2023, November 1, 2024 and November 1, 2025, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 5,000 RSUs for serving as a member of the Company's Board of Directors, 4,000 RSUs for serving on the Audit Committee and 1,800 RSUs for serving as the Chair of the Compensation Committee. F2 · balance_after: Includes 5,933 RSUs convertible into common stock originally granted on September 24, 2021. The RSUs vest in approximately two equal installments on October 1, 2023 and October 1, 2024, subject to accelerated vesting under certain conditions. F3 · balance_after: Includes 4,666 RSUs originally granted on November 20, 2020. The RSUs vest in approximately two equal installments on each of November 1, 2022, and November 1, 2023, subject to accelerated vesting under certain conditions. F4 · balance_after: Includes 37,801 vested RSUs in which the reporting person has elected to defer delivery until the reporting person's separation of service from the issuer or death or disability. Read SEC document
July 25, 2022 Filed Aug 3, 2022 20:02 UTC	Cocrystal Pharma, Inc. COCP · Entity 7621	GrantStock Options (Right to Buy) · Derivative	188,000	$0.00 Strike: $0.42	$0.00	Disclosure SEC source: 0001493152-22-021149 · ownership.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,000 Underlying: Common Stock · 188,000 shares Expires 2032-07-25 F1 · derivative.exercise_date: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 25, 2023 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2023, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date. Read SEC document
June 16, 2022 Filed Jun 21, 2022 23:10 UTC	Niagen Bioscience, Inc. CDXC · Entity 6146	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $1.64	$0.00	Disclosure SEC source: 0001628280-22-017724 · wf-form4_165585300854193.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: Option vests 100% on June 16, 2023. Read SEC document
June 15, 2022 Filed Jun 17, 2022 12:27 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	GrantStock Options (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.26	$0.00	Disclosure SEC source: 0001104659-22-072187 · tm2218714-5_4seq1.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. Read SEC document
September 24, 2021 Filed Sep 27, 2021 22:30 UTC	Red Violet, Inc. RDVT · Entity 4826	GrantCommon Stock	8,900	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-057836 · doc4.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,538 F1 · shares: On September 24, 2021, the reporting person received a grant of 8,900 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of October 1, 2022, October 1, 2023 and October 1, 2024, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 2,400 RSUs for serving as a member of the Company's Board of Directors, 5,000 RSUs for serving on the Audit Committee and 1,500 RSUs for serving as the Chair of the Compensation Committee. F1 · price: On September 24, 2021, the reporting person received a grant of 8,900 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of October 1, 2022, October 1, 2023 and October 1, 2024, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 2,400 RSUs for serving as a member of the Company's Board of Directors, 5,000 RSUs for serving on the Audit Committee and 1,500 RSUs for serving as the Chair of the Compensation Committee. F1 · balance_after: On September 24, 2021, the reporting person received a grant of 8,900 restricted stock units ("RSUs"), convertible into common stock of the issuer on a one-for-one basis, which vest in approximately three equal installments on each of October 1, 2022, October 1, 2023 and October 1, 2024, subject to accelerated vesting under certain conditions. The RSU grant includes an award of 2,400 RSUs for serving as a member of the Company's Board of Directors, 5,000 RSUs for serving on the Audit Committee and 1,500 RSUs for serving as the Chair of the Compensation Committee. F2 · balance_after: Includes 4,166 RSUs convertible into common stock originally granted on October 28, 2019. The RSUs vest on September 1, 2022, subject to accelerated vesting under certain conditions. F3 · balance_after: Includes 7,000 RSUs originally granted on November 20, 2020. The RSUs vest in approximately three equal installments on each of November 1, 2021, November 1, 2022, and November 1, 2023, subject to accelerated vesting under certain conditions. F4 · balance_after: Includes 28,334 vested RSUs in which the reporting person has elected to defer delivery until the reporting person's separation of service from the issuer or death or disability. Read SEC document
July 16, 2021 Filed Jul 20, 2021 20:05 UTC	Cocrystal Pharma, Inc. COCP · Entity 7621	GrantStock Options (Right to Buy) · Derivative	88,000	$0.00 Strike: $1.11	$0.00	Disclosure SEC source: 0001493152-21-017326 · ownership.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 88,000 shares Expires 2031-07-16 F1 · derivative.exercise_date: The stock options were issued pursuant to the 2015 Equity Incentive Plan and vest as follows: one-half will vest and become exercisable on July 16, 2022 and the remaining half will vest and become exercisable in eight equal quarterly installments on the last day of March, June, September, and December commencing on September 30, 2022, subject to the reporting person continuing to serve as a director of the Company on each applicable vesting date. Read SEC document
June 17, 2021 Filed Jun 22, 2021 21:27 UTC	Niagen Bioscience, Inc. CDXC · Entity 6146	GrantStock Options (right to buy) · Derivative	20,000	$0.00 Strike: $9.99	$0.00	Disclosure SEC source: 0001628280-21-012673 · wf-form4_162439717162695.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: Options vest 100% on June 17, 2022 Read SEC document
May 19, 2021 Filed May 20, 2021 20:10 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $1.48	$0.00	Disclosure SEC source: 0001415889-21-002609 · form4-05202021_040501.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document
February 19, 2021 Filed Feb 22, 2021 21:10 UTC	OPKO HEALTH, INC. OPK · Entity 4891	GrantStock Option (Right to Buy) · Derivative	350,000	$0.00 Strike: $4.81	$0.00	Disclosure SEC source: 0001209191-21-012670 · doc4.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director · Executive VP-Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2031-02-18 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning February 19, 2022. Read SEC document
November 20, 2020 Filed Nov 24, 2020 22:00 UTC	Red Violet, Inc. RDVT · Entity 4826	GrantCommon Stock	7,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-060253 · doc4.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,638 F1 · shares: On November 20, 2020, the reporting person received a grant of 7,000 restricted stock units ("RSUs"), convertible into common stock of the issuance on a one-for-one basis, which vest in approximately three equal installments on each of November 1, 2021, November 1, 2022, and November 1, 2023, subject to accelerated vesting under certain conditions. F1 · price: On November 20, 2020, the reporting person received a grant of 7,000 restricted stock units ("RSUs"), convertible into common stock of the issuance on a one-for-one basis, which vest in approximately three equal installments on each of November 1, 2021, November 1, 2022, and November 1, 2023, subject to accelerated vesting under certain conditions. F1 · balance_after: On November 20, 2020, the reporting person received a grant of 7,000 restricted stock units ("RSUs"), convertible into common stock of the issuance on a one-for-one basis, which vest in approximately three equal installments on each of November 1, 2021, November 1, 2022, and November 1, 2023, subject to accelerated vesting under certain conditions. F2 · balance_after: Includes 8,333 RSUs convertible into common stock originally granted on October 28, 2019. The RSUs vest in two equal installments on each of September 1, 2021 and September 1, 2022, subject to accelerated vesting under certain conditions. F3 · balance_after: Includes 8,333 RSUs convertible into common stock originally granted subject to both certain performance- and time-based criteria on September 5, 2018. As of June 30, 2019, the issuer deemed the performance criteria had been met. As a result of the meeting the performance criteria, the remaining RSUs vest on July 1, 2021, subject to accelerated vesting under certain conditions. F4 · balance_after: Includes 4,000 RSUs convertible into common stock originally granted on March 29, 2018. The RSUs vest on March 29, 2021, subject to accelerated vesting under certain conditions. F5 · balance_after: Includes 20,167 vested RSUs in which the reporting person has elected to defer delivery until the reporting person's separation of service from the issuer or death or disability. Read SEC document
August 26, 2020 Filed Aug 27, 2020 12:40 UTC	OPKO HEALTH, INC. OPK · Entity 4891	PurchaseCommon Stock	2,500	$4.01	$10,025.00	Disclosure SEC source: 0001209191-20-048491 · doc4.xml · nonDerivative · entry 3 Rubin Steven D · CIK 0001381874 · Director · Executive VP-Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,167,732 Read SEC document
August 26, 2020 Filed Aug 27, 2020 12:40 UTC	OPKO HEALTH, INC. OPK · Entity 4891	PurchaseCommon Stock	2,500	$3.99	$9,968.00	Disclosure SEC source: 0001209191-20-048491 · doc4.xml · nonDerivative · entry 2 Rubin Steven D · CIK 0001381874 · Director · Executive VP-Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,165,232 Read SEC document
August 26, 2020 Filed Aug 27, 2020 12:40 UTC	OPKO HEALTH, INC. OPK · Entity 4891	PurchaseCommon Stock	5,000	$3.99	$19,950.00	Disclosure SEC source: 0001209191-20-048491 · doc4.xml · nonDerivative · entry 1 Rubin Steven D · CIK 0001381874 · Director · Executive VP-Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,162,732 F1 · balance_after: Includes 413,585 shares received as a pro rata distribution from The Frost Group, LLC ("The Frost Group"), of which the reporting person is a member. The Frost Group effected a pro rata distribution of its 20,091,062 shares of the Issuer, pursuant to which reporting person now has direct beneficial ownership of his pro rata share of the securities formerly held by The Frost Group. The reporting person previously reported that the shares were owned directly by The Frost Group. Read SEC document
June 22, 2020 Filed Jun 24, 2020 20:05 UTC	Cocrystal Pharma, Inc. COCP · Entity 7621	GrantStock Options (Right to Buy) · Derivative	72,000	$0.00 Strike: $1.33	$0.00	Disclosure SEC source: 0001493152-20-011715 · ownership.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2030-06-22 F1 · derivative.exercise_date: The stock options vest as follows: 36,000 stock options will vest on the one year anniversary of the grant date and the remaining 36,000 stock options will vest in eight equal quarterly increments with the first such quarterly increment vesting on September 30, 2021. Read SEC document
June 19, 2020 Filed Jun 24, 2020 00:42 UTC	Niagen Bioscience, Inc. CDXC · Entity 6146	GrantStock Options (right to buy) · Derivative	20,000	$0.00 Strike: $4.67	$0.00	Disclosure SEC source: 0001415889-20-001675 · form4-06232020_050639.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: Options vest 100% on June 19, 2021. Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:14 UTC	OPKO HEALTH, INC. OPK · Entity 4891	GrantStock Option (Right to Buy) · Derivative	350,000	$0.00 Strike: $2.27	$0.00	Disclosure SEC source: 0001209191-20-034960 · doc4.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director · Executive VP-Administration 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning June 4, 2021. Read SEC document
May 20, 2020 Filed May 26, 2020 19:03 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $3.39	$0.00	Disclosure SEC source: 0001415889-20-001337 · form4-05262020_120530.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.